{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:32:21Z","timestamp":1760866341694,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12664-021-01172-w","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T05:02:25Z","timestamp":1635138145000},"page":"389-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-391X","authenticated-orcid":false,"given":"Debnarayan","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar","family":"Tatineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreenija","family":"Yarlagadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajinkya","family":"Gupte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sruthi K.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Madhavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haridas","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Sasidharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibu G.","family":"Pottayil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghavendra","family":"Holla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendran","family":"Sudhindran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-2006-939841","volume":"23","author":"A Ananthakrishnan","year":"2006","unstructured":"Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol. 2006;23:47\u201363.","journal-title":"Semin Intervent Radiol"},{"issue":"Suppl 1","key":"1172_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000333254","volume":"81","author":"D Sia","year":"2011","unstructured":"Sia D, Villanueva A. Signaling pathways in hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:18\u201323.","journal-title":"Oncology."},{"key":"1172_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin."},{"key":"1172_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/liv.13191","volume":"37","author":"J Im","year":"2016","unstructured":"Im J, Yoon S, Park H, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver International. 2016;37:90\u2013100.","journal-title":"Liver International."},{"key":"1172_CR5","doi-asserted-by":"crossref","unstructured":"OkudaK OT. Obata H, TomimatsuM, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985;56:918\u201328.","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","volume":"4","author":"S Yoon","year":"2018","unstructured":"Yoon S, Ryoo B, Lee S, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion. JAMA Oncol. 2018;4:661\u20139.","journal-title":"JAMA Oncol."},{"key":"1172_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-230X-14-84","volume":"14","author":"T Nakazawa","year":"2014","unstructured":"Nakazawa T, Hidaka H, Shibuya A, et al. Overall survival in response to sorafenib versus radiotherapyin unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14:84.","journal-title":"BMC Gastroenterol."},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1172_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ccr.2014.04.019","volume":"25","author":"J Llovet","year":"2014","unstructured":"Llovet J. Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. Cancer Cell. 2014;25:560\u20132.","journal-title":"Cancer Cell."},{"key":"1172_CR10","doi-asserted-by":"crossref","unstructured":"Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840\u20135.","DOI":"10.1053\/he.2000.5628"},{"key":"1172_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0360-3016(93)90428-X","volume":"27","author":"A Russell","year":"1993","unstructured":"Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993;27:117\u201323.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1172_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76:S3\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1172_CR13","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","volume":"76","author":"L Marks","year":"2010","unstructured":"Marks L, Yorke E, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10\u20139.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1172_CR14","unstructured":"Randomized Phase III Study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma. www.clinicaltrials.gov NCT No: NCT01730937"},{"key":"1172_CR15","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold A, Massey C, Kim J, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631\u20139.","journal-title":"J Clin Oncol."},{"key":"1172_CR16","doi-asserted-by":"crossref","unstructured":"Sun JX, Shi J, Li N, et al. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biol Med. 2016;13:452\u20138.","DOI":"10.20892\/j.issn.2095-3941.2016.0059"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/JCO.2017.35.15_suppl.4001","volume":"Suppl 35","author":"A Cheng","year":"2017","unstructured":"Cheng A, Finn R, Qin S, et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2017;Suppl 35:4001.","journal-title":"J Clin Oncol"},{"key":"1172_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.\u00a0Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"1172_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2017.35.4_suppl.344","volume":"Suppl 35","author":"R Finn","year":"2017","unstructured":"Finn R, Merle P, Granito A, et al. Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial. J Clin Oncol. 2017;Suppl 35:344.","journal-title":"J Clin Oncol"},{"key":"1172_CR20","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2018.36.15_suppl.4019","volume":"Suppl 36","author":"G Abou-Alfa","year":"2018","unstructured":"Abou-Alfa G, Meyer T, Cheng A, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial. J Clin Oncol. 2018;Suppl 36:4019.","journal-title":"J Clin Oncol"},{"key":"1172_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","volume":"100","author":"E Sapir","year":"2018","unstructured":"Sapir E, Tao Y, Schipper MJ, et al. Stereotactic body radiotherapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122\u201330.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1172_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/sajc.sajc_19_18","volume":"7","author":"D Dutta","year":"2018","unstructured":"Dutta D, Krishnamoorthy S, Sudahar H, Muthukumaran M, Ramkumar T, Govindraj J. Robotic radiosurgery treatment in liver tumors: Early experience from an Indian center. South Asian J Cancer. 2018;7:175\u201382.","journal-title":"South Asian J Cancer."},{"key":"1172_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/mco.2013.196","volume":"2","author":"J Kang","year":"2013","unstructured":"Kang J, Nie Q, Du R, et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol. 2013;2:43\u201350.","journal-title":"Mol Clin Oncol."},{"key":"1172_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/jrr\/rrw028","volume":"57","author":"Y Matsuo","year":"2016","unstructured":"Matsuo Y, Yoshida K, Nishimura H, et al. Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis\/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy. J Radiat Res. 2016;57:512\u201323.","journal-title":"J Radiat Res."},{"key":"1172_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.radonc.2017.11.013","volume":"129","author":"CH Rim","year":"2018","unstructured":"Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiat Oncol. 2018;129:112\u201322.","journal-title":"Radiat Oncol."},{"key":"1172_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3348\/kjr.2018.0496","volume":"20","author":"PH Kim","year":"2019","unstructured":"Kim PH, Choi SH, Kim JH, Park SH. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy. Korean J Radiol. 2019;20:385\u201398.","journal-title":"Korean J Radiol."},{"key":"1172_CR27","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.3748\/wjg.v25.i31.4360","volume":"25","author":"L Cerrito","year":"2019","unstructured":"Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol. 2019;25:4360\u201382.","journal-title":"World J Gastroenterol"},{"key":"1172_CR28","doi-asserted-by":"publisher","first-page":"33911","DOI":"10.18632\/oncotarget.15411","volume":"8","author":"JF Jiang","year":"2017","unstructured":"Jiang JF, Lao YC, Yuan BH, et al. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget. 2017;8:33911\u201321.","journal-title":"Oncotarget."},{"key":"1172_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S0360-3016(02)02846-8","volume":"53","author":"L Dawson","year":"2002","unstructured":"Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810\u201321.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1172_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.1976","volume":"105","author":"D Dutta","year":"2019","unstructured":"Dutta D, Kataki K, Turani T, Holla R. Prospective evaluation fiducial migration after placement for liver SBRT and influence on treatment delivery. Int J Radiat Oncol Biol Phys. 2019;105:E222. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.1976.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1172_CR31","doi-asserted-by":"crossref","unstructured":"Tatineni T, Kataki K. Madhavan R, Das R. Dutta D. Prognostication of HCC with PVT treated with SBRT: early results from a prospective study in India. Radiat Oncol. 2019;133:S759\u201360.","DOI":"10.1016\/S0167-8140(19)31814-6"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-021-01172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-021-01172-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-021-01172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T10:27:53Z","timestamp":1635416873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-021-01172-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1007\/s12664-021-01172-w","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"type":"print","value":"0254-8860"},{"type":"electronic","value":"0975-0711"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DD, TT, SY, AG, SKR, RM, HN, AS, RK, SGP, RH, and SS\u00a0declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed conforming to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible for the results\/findings and content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}